Terms: = Leukemia AND SH2B3, LNK, 10019, ENSG00000111252, Q9UQQ2 AND Treatment
15 results:
1. Tyrosine kinase inhibitor resistance in de novo BCR::ABL1-positive BCP-ALL beyond kinase domain mutations.
van Outersterp I; Boer JM; van de Ven C; Reichert CEJ; Boeree A; Kruisinga B; de Groot-Kruseman HA; Escherich G; Sijs-Szabo A; Rijneveld AW; den Boer ML
Blood Adv; 2024 Apr; 8(8):1835-1845. PubMed ID: 38386975
[TBL] [Abstract] [Full Text] [Related]
2. Genomic Mutation Profiles of Patients with Acute Myeloid leukemia in Korea: a Single-Center Experience.
Han E; Ryu S; Kim D; Koh EH; Byun JH; Lee DH
Clin Lab; 2023 Nov; 69(11):. PubMed ID: 37948498
[TBL] [Abstract] [Full Text] [Related]
3. Mutant
Goldberg L; Negi V; Chung YJ; Onozawa M; Zhu YJ; Walker RL; Pierce R; Patel DP; Krausz KW; Gonzalez FJ; Goodell MA; Rodriguez BAT; Meltzer PS; Aplan PD
Cancer Res; 2021 Oct; 81(19):5033-5046. PubMed ID: 34321240
[TBL] [Abstract] [Full Text] [Related]
4. Activated interleukin-7 receptor signaling drives B-cell acute lymphoblastic leukemia in mice.
Thomas KR; Allenspach EJ; Camp ND; Wray-Dutra MN; Khim S; Zielinska-Kwiatkowska A; Timms AE; Loftus JP; Liggitt HD; Georgopoulos K; Tasian SK; James RG; Rawlings DJ
Leukemia; 2022 Jan; 36(1):42-57. PubMed ID: 34193976
[TBL] [Abstract] [Full Text] [Related]
5. [Effect of Signal Transduction Pathway Gene Mutations on the One- course Induced Remission Rate and Analysis of Clinical Characteristics in Patients with CBF-AML].
Fan LF; Xu J; Chen XH; Tian TT; Xie J; Hu JJ; Guo ZP; Tan YH; Xu ZF; Ren FG; Zhang YF; Luo M; Ren WX; Wang HW
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2020 Jun; 28(3):781-788. PubMed ID: 32552936
[TBL] [Abstract] [Full Text] [Related]
6. Targeted next-generation sequencing in blast phase myeloproliferative neoplasms.
Lasho TL; Mudireddy M; Finke CM; Hanson CA; Ketterling RP; Szuber N; Begna KH; Patnaik MM; Gangat N; Pardanani A; Tefferi A
Blood Adv; 2018 Feb; 2(4):370-380. PubMed ID: 29467191
[TBL] [Abstract] [Full Text] [Related]
7. Leukemic Transformation in Myeloproliferative Neoplasms: A Literature Review on Risk, Characteristics, and Outcome.
Yogarajah M; Tefferi A
Mayo Clin Proc; 2017 Jul; 92(7):1118-1128. PubMed ID: 28688466
[TBL] [Abstract] [Full Text] [Related]
8. CBL family E3 ubiquitin ligases control JAK2 ubiquitination and stability in hematopoietic stem cells and myeloid malignancies.
Lv K; Jiang J; Donaghy R; Riling CR; Cheng Y; Chandra V; Rozenova K; An W; Mohapatra BC; Goetz BT; Pillai V; Han X; Todd EA; Jeschke GR; Langdon WY; Kumar S; Hexner EO; Band H; Tong W
Genes Dev; 2017 May; 31(10):1007-1023. PubMed ID: 28611190
[TBL] [Abstract] [Full Text] [Related]
9. Targetable kinase gene fusions in high-risk B-ALL: a study from the Children's Oncology Group.
Reshmi SC; Harvey RC; Roberts KG; Stonerock E; Smith A; Jenkins H; Chen IM; Valentine M; Liu Y; Li Y; Shao Y; Easton J; Payne-Turner D; Gu Z; Tran TH; Nguyen JV; Devidas M; Dai Y; Heerema NA; Carroll AJ; Raetz EA; Borowitz MJ; Wood BL; Angiolillo AL; Burke MJ; Salzer WL; Zweidler-McKay PA; Rabin KR; Carroll WL; Zhang J; Loh ML; Mullighan CG; Willman CL; Gastier-Foster JM; Hunger SP
Blood; 2017 Jun; 129(25):3352-3361. PubMed ID: 28408464
[TBL] [Abstract] [Full Text] [Related]
10. Polycythemia vera and essential thrombocythemia: 2017 update on diagnosis, risk-stratification, and management.
Tefferi A; Barbui T
Am J Hematol; 2017 Jan; 92(1):94-108. PubMed ID: 27991718
[TBL] [Abstract] [Full Text] [Related]
11. Deep targeted sequencing in pediatric acute lymphoblastic leukemia unveils distinct mutational patterns between genetic subtypes and novel relapse-associated genes.
Lindqvist CM; Lundmark A; Nordlund J; Freyhult E; Ekman D; Carlsson Almlöf J; Raine A; Övernäs E; Abrahamsson J; Frost BM; Grandér D; Heyman M; Palle J; Forestier E; Lönnerholm G; Berglund EC; Syvänen AC
Oncotarget; 2016 Sep; 7(39):64071-64088. PubMed ID: 27590521
[TBL] [Abstract] [Full Text] [Related]
12. Co-existence of IL7R high and sh2b3 low expression distinguishes a novel high-risk acute lymphoblastic leukemia with Ikaros dysfunction.
Ge Z; Gu Y; Xiao L; Han Q; Li J; Chen B; Yu J; Kawasawa YI; Payne KJ; Dovat S; Song C
Oncotarget; 2016 Jul; 7(29):46014-46027. PubMed ID: 27322554
[TBL] [Abstract] [Full Text] [Related]
13. Genetic alterations activating kinase and cytokine receptor signaling in high-risk acute lymphoblastic leukemia.
Roberts KG; Morin RD; Zhang J; Hirst M; Zhao Y; Su X; Chen SC; Payne-Turner D; Churchman ML; Harvey RC; Chen X; Kasap C; Yan C; Becksfort J; Finney RP; Teachey DT; Maude SL; Tse K; Moore R; Jones S; Mungall K; Birol I; Edmonson MN; Hu Y; Buetow KE; Chen IM; Carroll WL; Wei L; Ma J; Kleppe M; Levine RL; Garcia-Manero G; Larsen E; Shah NP; Devidas M; Reaman G; Smith M; Paugh SW; Evans WE; Grupp SA; Jeha S; Pui CH; Gerhard DS; Downing JR; Willman CL; Loh M; Hunger SP; Marra MA; Mullighan CG
Cancer Cell; 2012 Aug; 22(2):153-66. PubMed ID: 22897847
[TBL] [Abstract] [Full Text] [Related]
14. Octa-arginine mediated delivery of wild-type lnk protein inhibits TPO-induced M-MOK megakaryoblastic leukemic cell growth by promoting apoptosis.
Looi CY; Imanishi M; Takaki S; Sato M; Chiba N; Sasahara Y; Futaki S; Tsuchiya S; Kumaki S
PLoS One; 2011; 6(8):e23640. PubMed ID: 21853157
[TBL] [Abstract] [Full Text] [Related]
15. Myeloproliferative neoplasms: from JAK2 mutations discovery to JAK2 inhibitor therapies.
Passamonti F; Maffioli M; Caramazza D; Cazzola M
Oncotarget; 2011 Jun; 2(6):485-90. PubMed ID: 21646683
[TBL] [Abstract] [Full Text] [Related]
